Literature DB >> 22126728

Current management of muscle-invasive bladder cancer.

G Sancho1, P Maroto, J Palou.   

Abstract

Management of muscle-invasive bladder cancer (MIBC) has changed little in the last twenty years. The gold standard treatment is still cystectomy, but it has a significant negative impact on quality of life. Bladder-preservation strategies can be used in some cases but patient selection for this approach remains unclear. New chemotherapy and biologic agents in combination with surgery or radiotherapy could improve results and these possibilities are currently under investigation.

Entities:  

Mesh：

Year:  2011        PMID： 22126728     DOI： 10.1007/s12094-011-0746-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  74 in total

1.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

Authors:  Luigi Dogliotti; Giacomo Cartenì; Salvatore Siena; Oscar Bertetto; Andrea Martoni; Aldo Bono; Dino Amadori; Haluk Onat; Luca Marini
Journal:  Eur Urol       Date:  2006-12-26       Impact factor: 20.096

2.  Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.

Authors:  Ananya Choudhury; Ric Swindell; John P Logue; P Anthony Elliott; Jacqueline E Livsey; Marcus Wise; Paul Symonds; James P Wylie; Vijay Ramani; Vijay Sangar; Jeanette Lyons; Ian Bottomley; Damian McCaul; Noel W Clarke; Anne E Kiltie; Richard A Cowan
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

3.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

Authors:  D F Bajorin; P M Dodd; M Mazumdar; M Fazzari; J A McCaffrey; H I Scher; H Herr; G Higgins; M G Boyle
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

Review 4.  Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

Authors:  William U Shipley; Anthony L Zietman; Donald S Kaufman; John J Coen; Howard M Sandler
Journal:  Semin Radiat Oncol       Date:  2005-01       Impact factor: 5.934

Review 5.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

Authors:  D S Kaufman; K A Winter; W U Shipley; N M Heney; M P Chetner; L Souhami; R A Zlotecki; W T Sause; L D True
Journal:  Oncologist       Date:  2000

Review 7.  Trimodality treatment and selective organ preservation for bladder cancer.

Authors:  Claus Rödel; Christian Weiss; Rolf Sauer
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

8.  Oncological followup after radical cystectomy for bladder cancer-is there any benefit?

Authors:  Bjoern G Volkmer; Rainer Kuefer; Georg C Bartsch; Kilian Gust; Richard E Hautmann
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

9.  Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.

Authors:  Donatella Tirindelli Danesi; Giorgio Arcangeli; Enrico Cruciani; Pierluigi Altavista; Antonella Mecozzi; Bianca Saracino; Filina Orefici
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

10.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544
View more
  1 in total

1.  Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.

Authors:  Ajay Gopalakrishna; Thomas A Longo; Joseph J Fantony; Michael R Harrison; Brant A Inman
Journal:  Urol Oncol       Date:  2017-05-17       Impact factor: 3.498
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.